The Soaring Price of Diabetes Prescriptions in Upstate N.Y.

This report highlights the drivers behind the rising costs of diabetes prescriptions in upstate New York, and provides recommendations to those with diabetes.

This report highlights the drivers behind the rising costs of diabetes prescriptions in upstate New York, and provides recommendations to those with diabetes.

Background Info

The cost of treating diabetes is rising across the nation. According to a recent report from Express Scripts, the rising cost of diabetes prescriptions reflects an increase both in utilization and the unit cost of medications. Brand-name drugs continue to drive up costs, and a lack of generic medications provides few alternatives for those with diabetes. With more than 380,000 adults with diabetes in upstate New York, it is necessary to increase the awareness and understanding of the rising costs and the impact on our community.

Sources

Source URL
Excellus BlueCross BlueShield Claims Data, 2015
United States Department of Labor, Bureau of Labor Statisticshttp://www.bls.gov/cpi/
Express Scripts, 2015 Drug Trend Reporthttp://lab.express-scripts.com/lab/drug-trend-report
Zhuo, X., Zhang, P., Kahn, H.S., Bardenheier, B., Li, R., & Gregg, E. (2015). Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care, 38)4), 581-587.http://dx.doi.org/10.2337/dc14-1687
Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2015http://www.cdc.gov/brfss/annual_data/annual_2015.html
Greene, J., & Riggs, K. (2015). Why is there no generic insulin? Historical origins of a modern problem. The New England Journal of Medicine, 372(12), 1171. DOI: 10.1056/NEJMms1411398
U.S. Food and Drug Administration, “FDA approved Basaglar, the first ‘follow-on’ insulin glargine product to treat diabetes”http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm
Aikens, J., & Piette, J. (2013). Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes. Diabetic medicine, 30(3), 338-344. DOI: 10.1111/dme.12046
Choosing Wisely, Society of General Internal Medicinehttp://www.choosingwisely.org/clinician-lists/society-general-internal-medicine-daily-home-finger-glucose-testing-type-2-diabetes-mellitus/
Devine, S., Vlahiotis, A., & Sundar, H. (2010). A comparison of diabetes medication adherence and healthcare costs in patients using mail order pharmacy and retail pharmacy. Journal of Medical Economics, 13(2), 203-211. DOI: 10.3111/13696991003741801
Duru, O., Schmittdiel, J., Dyer, W., Parker, M., Uratsu, C., Chan, J., & Karter, A. (2010). Mail-order pharmacy use and adherence to diabetes-related medications. The American journal of managed care, 16(1), 33. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015238/pdf/nihms-257589.pdf
Lipska, K., Ross, J., Van Houten, H., Beran, D., Yudkin, J., & Shah, N. (2014). Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 to 2010. JAMA, 311(22), 2331-2333. doi: 10.1001/jama.2014.6316.
Science Daily, University of Michigan Health System. (2016, April 5). Sugar shock: Insulin costs tripled in 10 years, study finds.https://www.sciencedaily.com/releases/2016/04/160405122030.htm
U.S. Food and Drug Administration, Small Business Assistance: 180-Day Generic Drug Exclusivityhttp://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm069964.htm